Medicine and Dentistry
Radiation Therapy
100%
Neoplasm
40%
Malignant Neoplasm
32%
Overall Survival
30%
Prostate Cancer
29%
Clinical Trial
24%
Glioblastoma
24%
Disease
23%
Non Small Cell Lung Cancer
21%
Chemoradiotherapy
20%
Ganglioglioma
20%
Continuous Positive Airway Pressure
19%
Lung Cancer
19%
Epidermal Growth Factor Receptor
15%
Pancreas Cancer
15%
Stereotactic Body Radiation Therapy
14%
Biochemical Recurrence
14%
Computer Assisted Tomography
13%
Adjuvant Chemotherapy
12%
Radiosurgery
12%
Lymph Node
12%
Radiation Oncology
12%
Temozolomide
11%
Intensity Modulated Radiation Therapy
11%
Long Term Survival
11%
Prostate Specific Antigen
10%
Celiac Plexus
10%
Hazard Ratio
10%
Androgen Deprivation Therapy
10%
Cancer Cell
9%
Elderly Patient
9%
Breathing
9%
Recurrent Disease
9%
Radiosensitizer
9%
Immunotherapy
9%
Metastatic Carcinoma
8%
Adverse Event
8%
Pancreas Adenocarcinoma
8%
Phase I Trials
8%
Radiosensitivity
7%
Image-Guided Intervention
7%
Breast Cancer
7%
Biological Marker
7%
Proportional Hazards Model
7%
Stomach Adenocarcinoma
7%
Cediranib
7%
Combination Drug
7%
Radiosensitization
7%
Hypofractionated Radiotherapy
7%
Positron Emission Tomography
7%
Keyphrases
Radiation Therapy
67%
Radiotherapy
40%
Overall Survival
32%
Glioblastoma
20%
Continuous Positive Airway Pressure
20%
Radiosensitization
19%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
High-grade Glioma
18%
Tumor
18%
Prostate Cancer
17%
Radiosurgery
16%
Long-term Survival
15%
Androgen Deprivation Therapy
14%
Prostate-specific Antigen
14%
Biochemical Failure
14%
Temozolomide
13%
Cancer Patients
13%
Hazard Ratio
13%
Pancreatic Cancer
12%
Adjuvant Chemotherapy
12%
Local Control
12%
Chemotherapy
11%
Confidence Interval
11%
Neoadjuvant Chemoradiotherapy (nCRT)
11%
Non-small Cell Lung Cancer Patients
11%
Celiac Plexus
10%
Radiation Oncology
10%
Phase I Trial
10%
Clinical Outcomes
10%
Multivariate Analysis
9%
Prostate
9%
Prostate Cancer Patients
9%
Metastatic Colorectal Cancer (mCRC)
9%
Lung Cancer
9%
Ionizing Radiation
9%
Dose Escalation
9%
Lung
9%
Israel
9%
Elderly Patients
8%
Non-small Cell Lung Cancer (NSCLC)
8%
Locally Advanced
8%
Drug Combination
8%
Single Fraction
8%
Radiation Dose
7%
Brain Metastases
7%
Stereotactic Body Radiotherapy
7%
Combined Modality Therapy
7%
Pathological Stage
7%
Population Analysis
7%
Phase I Clinical Trial
7%